CDK7 and neoplasm: A more recent study found that CDK7 inhibition with samuraciclib increased expression of the immune checkpoint protein PD-L1 and increased infiltration of M1 macrophages and CD8+ cytotoxic T lymphocytes into TNBC tumours, which improved the efficacy of a PD-L1 inhibitor [164].